Nymox Pharma Files 20-F for FY2023

TL;DR

Nymox Pharma dropped its 2023 20-F, check it for prostate drug & cancer test updates.

AI Summary

Nymox Pharmaceutical Corp. filed its 20-F for the fiscal year ending December 31, 2023. The company is involved in the development of therapeutics for enlarged prostate and prostate cancer, as well as tobacco exposure tests. Financial details such as revenue and assets are presented in the filing.

Why It Matters

This filing provides investors and stakeholders with the official annual financial and operational overview of Nymox Pharmaceutical Corp., crucial for understanding its performance and future outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Nymox faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 1.81 — Revenue (Represents revenue for the fiscal year 2023.)
• 1.76 — Revenue (Represents revenue for the fiscal year 2022.)
• 6428000 — Assets (Total assets as of December 31, 2023.)
• 6080000 — Assets (Total assets as of December 31, 2022.)

Key Players & Entities

• NYMOX PHARMACEUTICAL CORP (company) — Filer of the 20-F report
• 2023-12-31 (date) — Fiscal year end for the report
• 20240829 (date) — Filing date of the report
• 0001018735 (company) — Central Index Key for Nymox Pharmaceutical Corp.

FAQ

Key Financial Figures

• $5.14 — on's stock fell approximately 82%, from $5.14 to $0.93. The clinical testing of drug
• $0.93 — k fell approximately 82%, from $5.14 to $0.93. The clinical testing of drug candidat
• $6.5 million — We incurred a net loss of approximately $6.5 million in 2022, and $7.9 million in 2023. As o
• $7.9 million — approximately $6.5 million in 2022, and $7.9 million in 2023. As of December 31, 2023, Nymox
• $207.1 million — s accumulated deficit was approximately $207.1 million and we have Negative cash flows from op
• $3,952,037 — Negative cash flows from operations of $3,952,037 for the year ended December 31, 2023. A
• $3,175,000 — 023, we had negative working capital of $3,175,000. We cannot say when, if ever, Nymox w
• $69,991 — ion had available cash of approximately $69,991 and a negative working capital of $3,17

Filing Documents

• nymox_20f.htm (20-F) — 1428KB
• nymox_ex12a.htm (EX-12.A) — 12KB
• nymox_ex12b.htm (EX-12.B) — 11KB
• nymox_ex13a.htm (EX-13.A) — 4KB
• nymox_ex13b.htm (EX-13.B) — 4KB
• 0001640334-24-001383.txt ( ) — 5835KB
• nymox-20231231.xsd (EX-101.SCH) — 105KB
• nymox-20231231_lab.xml (EX-101.LAB) — 309KB
• nymox-20231231_cal.xml (EX-101.CAL) — 55KB
• nymox-20231231_pre.xml (EX-101.PRE) — 271KB
• nymox-20231231_def.xml (EX-101.DEF) — 146KB
• nymox_20f_htm.xml (XML) — 1001KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Exchange Act). Yes No In this annual report, the terms "Nymox", "The Corporation", "The Company", "we" and "us" refers to both Nymox Pharmaceutical Corporation and its subsidiary, Nymox Corporation. Unless otherwise indicated all dollar amounts are in United States Dollars. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS You should be aware that this report contains forward-looking statements about, among other things, the anticipated operations, product development, financial condition and operating results of Nymox, proposed clinical trials and proposed transactions, including collaboration agreements. By forward-looking statements, we mean any statements that are not statements of historical fact, including (but not limited to) statements preceded by or that include the words, "believes", "expects", "anticipates", "hopes", "targets" or similar expressions. In connection with the "safe harbor" provisions in the Private Securities Litigation Reform Act of 1995, we are including this cautionary statement to identify some of the important factors that could cause Nymox's actual results or plans to differ materially from those projected in forward-looking statements made by, or on behalf of, Nymox. These factors, many of which are beyond the control of Nymox, include Nymox's ability to: Identify and capitalize on possible collaboration, strategic partnering or divestiture opportunities; Obtain suitable financing to support its operations and clinical trials; Successfully defend pending and/or unforeseeable future litigation; Manage its growth and the commercialization of its products; Achieve operating efficiencies as it progresses from a development-stage to a later-stage biotechnology corporation; Successfully compete in its markets; Succeed in finding and retaining joint venture and collaboration p

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not Applicable

OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not Applicable

KEY INFORMATION

ITEM 3. KEY INFORMATION

Selected Financial Data

Selected Financial Data The following table sets forth selected consolidated financial data for Nymox for the periods indicated, derived from financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") the financial statements have been audited by M&K CPAS, PLLC, of The Woodlands, in the United States as of December 31, 2023, and by TPS Thayer Company, LLC of Houston, Texas in the United States as of December 31, 2022, 2021, and 2020 and by Thayer O'Neal for the year ended December 31, 2019 and are reported in U.S. dollars. The data set forth below should be read in conjunction with the Corporation's consolidated financial statements and notes thereto included in Part I, Item 8 of this report. NYMOX PHARMACEUTICAL CORPORATION Selected Consolidated Financial Data (In U.S. dollars) Fiscal Year Ended December 31, 2023 2022 2021 2020 2019 Total Assets $ 626,540 $ 1,625,332 $ 1,442,843 $ 4,343,577 $ 5,489,286 Share Capital $ 173,816,208 $ 172,259,458 $ 165,061,049 $ 151,722,076 $ 136,554,101 Total Equity $ (3,173,274 ) $ (481,570 ) $ (505,968 $ 2,145,311 $ 3,448,246 Sales $ - $ - $ - $ 5,350 $ 115,648 Total Revenues (including sales) $ - $ - $ - $ 5,350 $ 115,648 Loss from operating activities $ (8,351,234 ) $ (6,651,641 ) $ (12,504,248 ) $ (11,719,323 ) $ (13,324,918 ) Net Loss $ (8,844,758 ) $ (6,575,922 ) $ (12,537,622 ) $ (11,737,761 ) $ (13,161,976 ) Loss per Share (basic & diluted) $ (0.10 ) $ (0.07 ) $ (0.15 ) $ (0.16 ) $ (0.19 ) Weighted Avg. No. of Common Shares 91,687,400 89,382,603 81,976,321 73,823,141 68,845,225 Nymox has never paid any dividends and does not expect to do so in the near future.

Risk Factors

Risk Factors Investing in our securities involves a significant degree of risk. You should carefully consider the risks described below, together with all of the other information in our publicly filed documents, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could be adversely affected. In such an event, the trading price of our Common Shares could decline, and shareholders may lose part or all of their investment in our securities. 2 We May Not Receive the Required Regulatory Approvals Necessary to Commercialize These Products our Therapeutic Products in Development, Such as Fexapotide Triflutate (NX-1207), Products requiring regulatory approval, such as Fexapotide Triflutate (NX-1207), will be approved for commercial sale only if governmental regulatory authorities are satisfied that our clinical trials are properly designed and conducted and that the results of those trials provide valid and acceptable evidence that the product is safe and effective for the conditions or diseases it is intended to treat. We do not know whether our already collected clinical trial results on a stand-alone basis and/or in combination with any future clinical trial results will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products. Clinical trials are lengthy, complex, expensive and uncertain processes and failure can occur at any stage of testing. If we fail to adequately demonstrate the safety and efficacy of our products under development, we will not be able to obtain the required regulatory approvals to commercialize our product candidates. On November 2, 2014, following the completion of data verification and auditing procedures, top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to place

View Full Filing

View this 20-F filing on SEC EDGAR